CMS Prolotherapy and Ligamentous Injection Coverage Policy: What Billing Teams Need to Know (NCD 15)

CMS's National Coverage Determination (NCD) 15 addresses one of the cleaner coverage calls in Medicare billing: prolotherapy, joint sclerotherapy, and ligamentous injections with sclerosing agents are non-covered services under Medicare. The Centers for Medicare & Medicaid Services modified this policy effective March 12, 2026, reaffirming the longstanding non-coverage position under §1862(a)(1) of the Social Security Act. If your practice or facility bills these services to Medicare patients, denial is the expected outcome—and your team needs to document and communicate accordingly.

What CMS NCD 15 Actually Says About Prolotherapy Coverage

The policy is direct. CMS has determined that the medical effectiveness of prolotherapy, joint sclerotherapy, and ligamentous injections with sclerosing agents has not been verified by scientifically controlled studies. Because clinical evidence does not meet the bar for "reasonable and necessary" care under §1862(a)(1) of the Act, Medicare will not reimburse these services.

This isn't a gray area or a "coverage with evidence development" situation. NCD 15 is a hard non-coverage determination that applies broadly under the Physicians' Services benefit category. There are no patient subgroups, diagnosis combinations, or clinical scenarios under which CMS will approve payment for these modalities.

The March 2026 modification does not introduce new covered indications. It reinforces that the non-coverage position remains in effect—which matters for billing teams that may have been watching for a policy reversal given growing clinical interest in regenerative injection therapies.

Why CMS Denies Prolotherapy Under §1862(a)(1)

Section 1862(a)(1) of the Social Security Act is the statutory foundation for Medicare's "reasonable and necessary" standard. For a service to be covered, CMS must have sufficient evidence that it is safe, effective, and appropriate for the Medicare population. Prolotherapy and related sclerosing agent injections have not cleared that bar.

The underlying rationale dates back decades but remains current policy. Prolotherapy involves injecting irritant solutions—commonly dextrose-based compounds or other sclerosants—into tendons, ligaments, or joint spaces to stimulate connective tissue repair. Despite a growing body of smaller clinical studies in the orthopedic and pain management literature, CMS has not determined this evidence meets the threshold for a positive coverage determination.

For billing managers: denials on this basis will carry a statutory non-coverage code, not a medical necessity determination tied to a specific clinical scenario. That distinction matters when explaining denials to patients and when deciding whether to pursue appeals.

Prior Authorization and Medical Necessity Requirements Under NCD 15

Because NCD 15 is a blanket non-coverage determination, prior authorization is not the relevant workflow here—there is no authorization pathway that results in Medicare payment for these services. Submitting a prior authorization request will not unlock coverage.

Medical necessity documentation, while always best practice, will also not overcome a statutory exclusion under §1862(a)(1). A detailed clinical note explaining why a patient needs prolotherapy does not change CMS's position that the therapy's effectiveness has not been scientifically verified.

The operative compliance requirement is the Advance Beneficiary Notice of Noncoverage (ABN), Form CMS-R-131. Before furnishing a non-covered service to a Medicare beneficiary, providers must issue a valid ABN so the patient can make an informed decision about whether to receive the service and accept financial responsibility. Failure to issue an ABN appropriately can leave your practice liable for the cost.

Affected Codes

This policy does not list specific CPT or HCPCS codes. The policy data for NCD 15 contains no covered codes, no explicitly listed non-covered codes, and no associated ICD-10-CM diagnosis codes.

Practical implication for billing teams: The absence of specific codes in the NCD itself means you should cross-reference your clearinghouse's Medicare claims edits and your Medicare Administrative Contractor's (MAC) local policies to identify which CPT codes are most commonly associated with prolotherapy claims in your region. Common procedure codes used to bill these services in non-Medicare contexts—such as injection codes in the musculoskeletal and spine sections of the CPT book—will be denied under NCD 15 when billed to Medicare, even if they are not enumerated in the NCD text itself.

Consult your MAC's local coverage article (LCA) associated with NCD 15 for any supplemental code-level guidance applicable to your jurisdiction.

Medicare ABN Requirements for Prolotherapy Services

When a service is excluded by a national coverage determination, the ABN process is your primary patient protection mechanism. Here's what that means operationally:

The ABN must be issued before the service is rendered—not after. It must include a description of the specific service, the reason Medicare is expected to deny payment (reference the non-coverage determination), and an estimate of the patient's cost. Patients must sign and date the form, and a copy must be retained in the medical record.

If a patient declines the ABN and you provide the service anyway, you cannot bill the patient. If the ABN is issued properly and the patient accepts financial responsibility, you can collect from the patient directly. Getting this process right protects your practice from writing off charges that should have been disclosed upfront.

What Your Billing Team Should Do